Thymosin Alpha-1 Adult Dosing (Ages 30 to 49): Evidence, Protocols, and Clinical Guidance
At a glance
- Standard trial dose / 1.6 mg subcutaneous injection, twice weekly, roughly 3 to 4 days apart
- Peptide identity / 28-amino-acid peptide, sequence-identical to endogenous thymosin alpha-1
- FDA status (US) / not FDA-approved for any indication; available only through 503A compounding with a prescription
- International status / marketed abroad under the brand Zadaxin for chronic hepatitis B in some countries; exact country count and current status should be confirmed with the manufacturer or local regulator before citing a number
- Evidence base / randomized trials exist in chronic hepatitis B and hepatitis C, and in cancer-adjunct settings; general immune-support use in healthy adults 30 to 49 is off-label and not separately trial-tested
- Storage / reconstituted vials are generally kept refrigerated; exact stability windows vary by compounding pharmacy and should be confirmed against that pharmacy's documentation
Direct answer
Thymosin alpha-1 (thymalfasin) is a synthetic version of a peptide the thymus gland produces naturally. In clinical trials for chronic hepatitis B and hepatitis C, and as an adjunct in some cancer treatment studies, the dose used was consistently 1.6 mg injected subcutaneously twice per week, spaced three to four days apart, for treatment courses ranging from several weeks to about a year. It is not FDA-approved in the United States for any use; where prescribed, it comes from a 503A compounding pharmacy rather than a manufactured drug product. Using this same dose for general immune support in adults without hepatitis or cancer is an off-label extrapolation from that trial evidence, not a separately validated protocol, and no trial has specifically evaluated outcomes in a healthy 30-to-49 population.
What thymosin alpha-1 is, and what it is not
Thymosin alpha-1 is a 28-amino-acid peptide first isolated from thymic tissue in the 1970s. It is distinct from thymosin beta-4 (sometimes sold as TB-500), which is a different peptide involved in tissue repair rather than immune modulation, and from thymulin, a separate zinc-dependent thymic peptide with a much smaller human evidence base. Confusing these names is common in the peptide-supplement market, so it is worth stating plainly: thymosin alpha-1 refers specifically to the immune-modulating peptide discussed here, marketed internationally under the brand name Zadaxin, and available in the US only as thymalfasin through compounding.
Thymic hormone output is understood to decline with age starting around puberty, but the exact magnitude of decline by the fourth decade of life is not something this article can state as a precise, sourced figure. Readers should treat specific numeric claims about age-related decline (for example, a stated percentage drop by a certain age) as plausible physiology rather than an established, citable statistic unless a specific study is checked and confirmed.
The dosing protocol used in published trials
The dose appearing across the majority of published thymosin alpha-1 trials is 1.6 mg given subcutaneously twice weekly, with doses spaced roughly three to four days apart (for example, Monday and Thursday). This is a fixed dose, not weight-based. Trial pharmacokinetic work generally describes a short serum half-life (on the order of a couple of hours after subcutaneous injection), with peak concentration reached within one to two hours. The twice-weekly interval reflects the idea that downstream immune signaling outlasts the drug's presence in serum, though the exact duration of that downstream effect is better described as "several days" than as a precise hour count without checking the specific study.
A typical trial schedule injects 1.6 mg on two set days each week, three to four days apart. There is no published head-to-head comparison establishing that one specific day pairing outperforms another; consistency of spacing appears to matter more than which two days are chosen.
Injection technique
Subcutaneous injection is the route studied in the published literature. The abdomen, with rotation of injection sites away from the navel, and the outer thigh are typical locations used in clinical and compounding-pharmacy guidance. Reconstitution steps vary by pharmacy: lyophilized (freeze-dried) vials are typically reconstituted with bacteriostatic water and mixed by gentle swirling rather than shaking. Exact reconstitution volumes, needle gauge recommendations, and stability windows after reconstitution differ by compounding pharmacy, and the pharmacy's own instructions should take precedence over generic guidance.
Rotating injection sites reduces the chance of localized skin changes at repeated injection points. Vials generally require refrigeration; travelling with an insulated case and cold packs is a reasonable practical step, but specific stability claims (how many days a reconstituted vial remains usable) should be confirmed with the dispensing pharmacy rather than assumed.
What the trial evidence actually supports
The strongest published evidence for thymosin alpha-1 comes from randomized trials in chronic hepatitis B and, to a lesser extent, hepatitis C, generally using thymalfasin 1.6 mg twice weekly for treatment courses of roughly six months to a year, sometimes combined with interferon-based therapy. These trials reported improved virologic response compared with control arms in some analyses, though the size of that benefit and its statistical confidence vary by study and by whether thymalfasin was used alone or alongside interferon. Cancer-adjunct data, generally involving thymalfasin given alongside chemotherapy, has reported improvements in immune markers such as CD4/CD8 ratio and, in some analyses, survival outcomes in specific cancers such as hepatocellular carcinoma treated with transarterial chemoembolization. This cancer-adjunct evidence is earlier-stage and more heterogeneous than the hepatitis B trial base.
Two limits matter for a reader in this age bracket. First, none of the identified trials isolate a 30-to-49-year-old healthy population; all of the controlled evidence comes from patients with a specific disease (chronic viral hepatitis, cancer, or in one case severe sepsis). Second, the specific PMIDs and journal citations attached to this evidence in earlier drafts of this material could not be independently verified in this revision and should be checked against the primary literature before being published with exact citation numbers, sample sizes, or effect-size figures (such as a specific percentage response rate or risk ratio). Until that verification happens, this article describes the evidence in general terms rather than repeating precise statistics that cannot currently be confirmed.
The US FDA regulatory position on thymalfasin has not changed: it is not an FDA-approved drug, and no FDA-approved label exists to set an approved dose, indication, or monitoring schedule (FDA compounding laws and policies). Everything above the FDA line in the evidence hierarchy, meaning an approved label or an accountable clinical guideline specific to thymosin alpha-1, does not exist for this compound in the United States. What exists below that line is trial evidence in specific disease populations, which is weaker support than a label and should not be read as label-equivalent guidance for off-label immune-support use.
Dose adjustments and situations that need individualized judgment
The 1.6 mg twice-weekly protocol is unusually consistent across the trial literature that does exist, but a few scenarios call for a conversation with a prescriber rather than self-directed adjustment:
- Loading or induction dosing. Some critical-care and sepsis studies used daily dosing for a short induction period before returning to a twice-weekly schedule. This has not been validated for outpatient, non-critical-illness use, and there is no published pharmacokinetic support for daily loading improving outcomes in otherwise healthy adults.
- Extended or cycled protocols. Hepatitis trials generally ran six months to a year continuously. Shorter 8-to-12-week cycles with a washout period, sometimes used in off-label immune-support settings, are a theoretical construct based on avoiding immune tolerance rather than a tested protocol.
- Kidney disease. Thymosin alpha-1 is understood to be cleared by peptide degradation rather than renal filtration, which is the rationale usually given for not requiring dose reduction in mild-to-moderate kidney disease. Patients with significant kidney impairment should still raise this with their prescriber, since pharmacokinetic data specific to that population is limited.
- Liver disease. Because the largest trial populations had chronic hepatitis, thymalfasin has been administered in patients with meaningful liver disease, including compensated cirrhosis, in a trial setting. That is different from an individualized recommendation for a specific patient's liver function, which requires a clinician's review of that patient's labs.
- Autoimmune disease. Thymosin alpha-1 is understood to push immune activity toward a Th1-dominant profile. In theory, this could aggravate a Th1-associated autoimmune condition such as Hashimoto's thyroiditis or rheumatoid arthritis. No trial has confirmed or quantified this risk. Patients with a known autoimmune diagnosis should discuss baseline inflammatory markers and monitoring with their prescriber before starting.
Safety signals reported in the literature
Across the hepatitis B and hepatitis C trial literature, thymosin alpha-1 has generally been described as well tolerated, with adverse event rates in treated groups not clearly different from control groups in several analyses. Commonly reported effects include mild injection-site redness or soreness and transient fatigue or flu-like symptoms after early injections. Reports of serious adverse events specifically attributed to thymalfasin at the 1.6 mg dose are uncommon in the published record reviewed for this article, but a full, current safety review has not been independently re-verified for this draft, so this should be read as "no major safety signal identified in the sources checked" rather than "proven safe for all uses." Thymosin alpha-1's mechanism is immune-modulating rather than immune-suppressing, which is a meaningful distinction from corticosteroids or conventional immunosuppressants, but that distinction does not remove the need for monitoring, particularly in anyone with autoimmune disease or a history of unusual immune reactions.
Anyone who develops fever, significant swelling, breathing difficulty, or signs of an allergic reaction after an injection should stop the medication and seek urgent medical care rather than waiting for a scheduled follow-up.
How thymosin alpha-1 compares with other peptides adults in this age group encounter
| Peptide | Primary studied mechanism | Human trial depth | Common confusion |
|---|---|---|---|
| Thymosin alpha-1 (thymalfasin) | Dendritic cell activation, Th1-biased immune modulation | Multiple randomized trials in hepatitis B/C and cancer-adjunct settings | Confused with thymosin beta-4 due to similar name |
| Thymosin beta-4 (TB-500) | Tissue repair, angiogenesis | Different evidence base, not immune-modulating | Sometimes marketed as interchangeable with thymosin alpha-1; it is not |
| BPC-157 | Gastric/anti-inflammatory, wound healing | Limited human trial data | Sometimes "stacked" with thymosin alpha-1 without trial support for the combination |
| Thymulin | T-cell maturation support | Sparse human data, no standardized exogenous dosing protocol | Assumed to be a direct substitute for thymosin alpha-1; the evidence base does not support that assumption |
No trial has tested combining thymosin alpha-1 with BPC-157 or thymosin beta-4. Any decision to combine peptides rests on individual clinical judgment, not on trial data, and should be made with a prescriber who can weigh the specific reason for combining them.
A framework for the prescriber conversation and monitoring
The material below is a structure for a conversation with a prescriber, not a substitute for one. It separates what trial evidence and FDA status establish from what depends on an individual patient's history and labs.
Before starting
| Checkpoint | What it establishes | Who decides |
|---|---|---|
| Confirm the indication | Is this for a studied use (chronic hepatitis, cancer adjunct) or off-label general immune support? The evidence strength differs materially between these. | Prescriber, based on diagnosis |
| Screen for autoimmune history | Th1-biased immune shift is a theoretical concern in Th1-associated autoimmune disease | Prescriber, with patient history |
| Baseline labs | CBC with differential, comprehensive metabolic panel, and any disease-specific markers the prescriber considers relevant | Prescriber, tailored to the patient |
| Confirm sourcing | Verify the compounding pharmacy is 503A-licensed and the prescription is valid, since thymalfasin has no FDA-approved manufactured version to fall back on | Patient and prescriber together |
During treatment (first 6 to 8 weeks)
| Checkpoint | Established signal | Escalation trigger |
|---|---|---|
| Injection-site review | Mild redness or soreness is commonly reported and usually self-limited | Spreading redness, warmth, or fever suggests possible infection; seek care rather than continuing the schedule |
| Systemic symptoms | Transient fatigue or flu-like feeling after early doses has been reported | New joint pain, rash, or worsening of a pre-existing autoimmune condition should prompt a call to the prescriber before the next dose |
| Adherence to spacing | Twice-weekly spacing of three to four days is the pattern used in trials | Significant deviation (daily dosing, or gaps of more than a week) moves outside the studied pattern and should be discussed rather than self-adjusted |
Stop or escalate immediately if:
- Signs of an allergic reaction appear (swelling of the face or throat, difficulty breathing, hives)
- Fever or systemic illness develops that is not clearly explained by something else
- A pre-existing autoimmune condition visibly worsens after starting
What sits outside label guidance entirely: because there is no FDA-approved label for thymalfasin, there is no official dosing table, no official monitoring schedule, and no official list of contraindications to defer to. Everything above is drawn from trial protocols in specific diseases and general pharmacologic reasoning. A prescriber's individualized judgment, informed by the patient's own history and labs, carries more weight here than any generic protocol, including this one.
Evidence boundary: what is established, what is plausible, what is not established
Established: Thymalfasin is not FDA-approved in the United States and is obtained only through prescription-based 503A compounding. Randomized trials in chronic hepatitis B, and smaller trials in hepatitis C and cancer-adjunct settings, have used 1.6 mg subcutaneous dosing twice weekly.
Plausible but unproven: That this same dosing pattern produces meaningful immune benefit in healthy adults aged 30 to 49 using it for general immune support rather than a diagnosed disease. That cycling 8 to 12 weeks on with a washout period improves outcomes compared with continuous dosing. That thymosin alpha-1 meaningfully worsens Th1-associated autoimmune disease.
Not established: A validated dosing protocol specific to healthy adults without hepatitis or cancer. Long-term safety data outside of the disease populations studied. Any officially recognized indication, dose, or monitoring standard from FDA or a clinical guideline body, since none currently exists for this compound in the US.
Getting thymosin alpha-1 in the United States
Thymalfasin is not sold at retail pharmacies. It is compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act by state-licensed compounding pharmacies, and requires a prescription from a licensed prescriber (FDA compounding laws and policies). Because it is compounded rather than FDA-approved, it is not subject to the same manufacturing oversight as an approved drug product, and insurance coverage is generally not available. Cost varies by pharmacy and formulation (lyophilized vial versus pre-filled syringe); readers should get a current quote directly from a licensed compounding pharmacy rather than relying on a fixed price figure, since compounding costs change over time and by region.
Frequently asked questions
What is the standard dose of thymosin alpha-1 used in clinical trials?
Is thymosin alpha-1 FDA-approved?
Does the trial dosing protocol apply to general immune support in a healthy adult?
What side effects have been reported?
Could thymosin alpha-1 worsen an autoimmune condition?
Is thymosin alpha-1 the same as thymosin beta-4?
References
- U.S. Food and Drug Administration. Compounding laws and policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
A note on sourcing for this revision: the PubMed identifiers attached to specific trial claims in earlier material (hepatitis B and C response rates, cancer survival risk ratios, sample sizes, and a quoted statement attributed to a named researcher) could not be independently verified against the primary literature during this revision, and a targeted PubMed search did not return a confirmed match to attach to those specific numbers. Those precise figures and the quotation have been removed rather than carried forward. Before this article is published, the specific trials behind the hepatitis B/C response-rate and cancer-adjunct survival claims should be located, cited by verified PMID or DOI, and any figures reinstated only with a confirmed source attached.